SHINE · BHV7000-304
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A multicenter, randomized, double-blind, placebo-controlled phase 2/3 study evaluating the efficacy, safety and tolerability of adjunctive BHV-7000 in participants with idiopathic generalized epilepsy and generalized tonic-clonic seizures, followed by an open-label extension. EudraCT: 2023-508812-45-00.
Sponsor: Biohaven
Phase: II
Area: Epilepsy